Pembrolizumab, an anti-PD-1 agent, has been evaluated in the PEARLS/KEYNOTE-091 trial (NCT02504372), a phase III randomized study including 1177 patients with resected stage IB–IIIA NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.